Analysis: Data mining for drug safety

03/8/2007 | RPM Report (free registration), The

The FDA, as part of its drug safety overhaul, could adopt data mining to speed and improve the review of drug safety as new products move into the market, which might ease pressure on the FDA during the pre-market approval process, The RPM Report writes. However, some are worried the tools could lead to an inflated number of safety concerns, dangerous competitive tools and a minimization of FDA power in determining drug safety.

View Full Article in:

RPM Report (free registration), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
San Jose, CA
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA